ClinicalTrials.gg

Program

selpercatinib

Also written as “Selpercatinib”, “[14C]-Selpercatinib” and “LOXO-292”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Carcinoma, Medullary · Thyroid Neoplasms · Renal Insufficiency, led by Eli Lilly.

Furthest: phase 4, since Sep 11, 202619 company-led studies, 7 open or runningNext primary completion: Oct 2029 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lilly197 open or runningphase 4since Sep 11, 2026May 9, 2017Oct 2029phase 4 · NCT07822880

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 9, 2017First study: phase 2 study in Carcinoma, Non-Small-Cell LungFirst studyNCT03157128 · 857 enrolled · United States, Australia, Canada and more
  2. Feb 6, 2019Phase 2 study in Carcinoma, MedullaryNCT03899792 · 36 enrolled · United States, Australia, Canada and more
  3. Dec 9, 20192 phase 3 studiesNCT04194944, NCT04211337
  4. Feb 20, 2020Phase 2 study in Carcinoma, MedullaryNCT04280081 · 77 enrolled · China
  5. Mar 2, 2021Phase 1 study in HealthyNCT04782076 · 36 enrolled · United States
  6. Mar 25, 2021Phase 3 study in Carcinoma, Non-Small-Cell LungNCT04819100 · 152 enrolled · United States, Australia, Austria and more
  7. Oct 21, 2021Phase 1 study in HealthyNCT05089019 · 224 enrolled · United States
  8. Nov 25, 2021Phase 1 study in HealthyNCT05136404 · 42 enrolled · United States
  9. Apr 5, 20223 phase 1 studies in HealthyNCT05324124, NCT05338515, NCT05338502
  10. Jun 24, 2022Phase 1 study in HealthyNCT05436912 · 36 enrolled · United States
  11. Jul 19, 20222 phase 1 studiesNCT05468164, NCT05469100
  12. Nov 21, 20222 phase 1 studies in HealthyNCT05630287, NCT05630274
  13. Jun 8, 2023Phase 1 study in HealthyNCT05906836 · 28 enrolled · United States
  14. Sep 11, 2026Phase 4 study in Thyroid NeoplasmsNCT07822880 · 30 planned · India

Ahead

  1. Oct 2029Primary completion: phase 4 study in Thyroid NeoplasmsNCT07822880

TargetBeta

“An orally bioavailable selective inhibitor of wild-type, mutant and fusion products involving the proto-oncogene receptor tyrosine kinase rearranged during transfection (RET), ”NCIt, by rule
“Tyrosine-protein kinase receptor RET inhibitor; Kinesin-1 heavy chain/ Tyrosine-protein kinase receptor RET inhibitor; Coiled-coil domain-containing protein 6/Tyrosine-protein kinase receptor RET inhibitor”ChEMBL 37, by rule

Other programs on the same three targets

ProgramCompanyFurthest phaseStudies
pralsetinibruleHoffmann-La Rochephase 47

Studies

All 19 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07822880Thyroid Neoplasms · India4Not yet recruitingOct 202930
NCT05906836Healthy · United States1CompletedOct 31, 202328
NCT05630287Healthy · United States1CompletedSep 24, 201812
NCT05630274Healthy · United States1CompletedJun 21, 201932
NCT05469100Renal Insufficiency · United States1CompletedAug 7, 201937
NCT05468164Healthy · United States1CompletedSep 13, 201820
NCT05436912Healthy · United States1CompletedOct 4, 201936
NCT05338515Healthy · United States1CompletedMar 12, 201918
NCT05338502Healthy · United States1CompletedSep 3, 201920
NCT05324124Healthy · Singapore1CompletedJun 22, 202246
NCT05136404Healthy · United States1CompletedMar 14, 202242
NCT05089019Healthy · United States1CompletedJul 19, 2022224
NCT04819100Carcinoma, Non-Small-Cell Lung · United States, Australia, Austria and more3Active, not recruitingJan 12, 2026152
NCT04782076Healthy · United States1CompletedMay 17, 202136
NCT04280081Carcinoma, Medullary · China2Active, not recruitingMar 25, 202177
NCT04211337Carcinoma, Medullary · United States, Australia, Belgium and more3Active, not recruitingMay 22, 2023291
NCT04194944Carcinoma, Non-Small-Cell Lung · Argentina, Australia, Belgium and more3Active, not recruitingMay 1, 2023261
NCT03899792Carcinoma, Medullary · United States, Australia, Canada and more2Active, not recruitingNov 8, 202436
NCT03157128Carcinoma, Non-Small-Cell Lung · United States, Australia, Canada and more2Active, not recruitingFeb 14, 2025857

How it is read

Names in the registry

  • “Selpercatinib”, 17 entries
  • “[14C]-Selpercatinib”, 2 entries
  • “LOXO-292”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.